Pfizer (PFE) Stock Price, Chart, Company Profile & AI Analysis

Key Takeaways

• Pfizer shares traded near $25.05 in mid-July 2026, roughly flat over the prior 30 days but down approximately 9% from mid-April levels, reflecting persistent investor caution.
• The stock remains below both its 50-day and 200-day simple moving averages, signaling subdued near-term momentum and an unestablished long-term uptrend.
• Declining COVID-19 product revenues and an approaching patent cliff on blockbuster drugs including Eliquis and Ibrance continue to weigh on sentiment.
• Pfizer's oncology franchise, bolstered by the Seagen acquisition, delivered 7% revenue growth in Q1 2026, while recently launched and acquired products posted double-digit gains.
• The company's 6.9% dividend yield remains among the highest in the pharmaceutical sector, though a payout ratio above 130% fuels ongoing debate about dividend sustainability.
• Wall Street consensus rates PFE a Hold with an average 12-month price target of approximately $28.50, implying a potential upside of roughly 14% from current levels.

Current Market Snapshot

Pfizer Inc. (PFE) shares closed at $25.05 on July 17, 2026, capping a period of relative stability after a sharper drawdown in late June. The stock has drifted within a tight band between roughly $23.70 and $25.65 over the past several weeks, reflecting a market that is neither convinced the worst is over nor willing to abandon the name entirely. Trading at approximately 8.5 times forward earnings, Pfizer remains deeply discounted relative to large-cap pharmaceutical peers such as Eli Lilly, Novo Nordisk, and AbbVie. The stock's beta of 0.35 indicates low volatility relative to the broader market, consistent with a mature pharmaceutical giant navigating a challenging transition period. Institutional ownership stands at approximately 68%, though some large holders trimmed positions during the first quarter of 2026.

Pfizer (PFE) Business Overview and Competitive Position

Pfizer is one of the world's largest biopharmaceutical companies, with a portfolio spanning oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care, and vaccines. Founded in 1849 and headquartered in New York City, the company researches, develops, manufactures, and commercializes medicines and vaccines across more than 125 countries. Oncology has become Pfizer's most important growth engine, contributing roughly 27% of total revenues, a position meaningfully strengthened by the $43 billion acquisition of Seagen in 2023. Key oncology drugs include Padcev, Lorbrena, and the Braftovi-Mektovi combination. Outside oncology, the cardiovascular franchise — anchored by Eliquis and Vyndaqel — and the migraine treatment Nurtec represent significant revenue contributors. Pfizer's COVID-19 vaccine Comirnaty and antiviral Paxlovid generated extraordinary revenues during the pandemic but have since declined sharply, forcing the company to pivot toward its non-COVID portfolio and pipeline. Strategic acquisitions of Metsera and Biohaven, along with a licensing deal with Chinese biotech 3SBio, underscore Pfizer's effort to rebuild its pipeline in obesity and next-generation oncology.

Recent Developments Driving PFE

Several developments have shaped investor sentiment around Pfizer in recent weeks. On the positive side, the company received FDA approval for a Padcev plus Keytruda regimen in muscle-invasive bladder cancer, expanding the commercial opportunity for one of its key oncology assets. Q1 2026 results, reported in early May, showed adjusted earnings of $0.75 per share on revenue of $14.45 billion — both above consensus estimates — while management reaffirmed full-year 2026 guidance of $2.80 to $3.00 in adjusted EPS on revenue of $59.5 billion to $62.5 billion. Pfizer's board also declared a $0.43 quarterly dividend in late June, marking the 351st consecutive quarterly dividend payment and reinforcing management's stated commitment to the payout.

On the negative side, Erste Group Bank trimmed its FY2026 EPS estimate to $2.92 from $2.95 in mid-July, while HSBC downgraded the stock from Buy to Hold with a reduced price target of $28. Wall Street Zen also lowered its rating from Buy to Hold. Arbutus Biopharma initiated international patent infringement lawsuits against Pfizer and BioNTech related to lipid nanoparticle technology used in mRNA vaccines, introducing legal uncertainty. Additionally, Pfizer suspended sales of Premarin vaginal cream in India due to supply chain challenges. These headwinds, combined with ongoing concerns about the patent cliff and declining COVID revenues, have kept the stock anchored below key moving averages.

Trending AI Robots

For traders seeking data-driven insights beyond traditional fundamental analysis, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots actively deployed across thousands of tickers. Tickeron hosts hundreds of algorithmic trading bots, each employing distinct strategies, timeframes, and performance metrics tailored to different market conditions. Only the top-performing and most relevant bots appear in the Trending section, making it a focused resource for those looking to complement their research with quantitative signals. Whether a bot specializes in swing trading, trend following, or mean-reversion strategies, the platform provides transparency into historical performance so users can evaluate what aligns with their approach. Exploring the Trending AI Robots page can help investors identify which automated strategies are currently gaining traction in real-time markets.

2026 Outlook and What Investors Should Watch

Looking ahead through the remainder of 2026, several factors will determine whether Pfizer can stabilize and eventually reverse its multi-year decline. The most immediate catalyst is the Q2 2026 earnings report, where investors will scrutinize non-COVID operational revenue growth, progress on cost-reduction initiatives, and any updates to full-year guidance. The company expects recently launched and acquired products to sustain double-digit growth, and execution on that front will be critical. The obesity pipeline represents Pfizer's most significant long-term opportunity: the company plans to initiate over 20 obesity-related studies in 2026, including 10 Phase III trials for berobenatide, its monthly GLP-1 receptor agonist acquired through the Metsera deal. First potential approvals in obesity are not expected until 2028, however, and Pfizer trails well-established leaders Eli Lilly and Novo Nordisk.

On the risk side, the patent cliff looms large. Ibrance loses exclusivity in 2027, followed by Eliquis and Vyndaqel in 2028. Pfizer expects approximately $1.5 billion in lost revenue from loss of exclusivity in 2026 alone. The sustainability of the dividend — with a payout ratio exceeding 130% of trailing earnings — remains a key question, though management has consistently emphasized maintaining the dividend as a capital allocation priority. Macroeconomic factors including interest rate policy and healthcare regulatory developments under the current administration could also influence the stock. With a forward P/E below 9 and a nearly 7% dividend yield, Pfizer presents a complex risk-reward profile that will likely remain a topic of debate among value-oriented and income-focused investors throughout 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.